Monday, July 7, 2025
News Health
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
HealthNews
No Result
View All Result
Home Health News

Methotrexate Adds No Benefit to Adalimumab in Psoriasis

June 4, 2025
in Health News
Share on FacebookShare on Twitter


TOPLINE:

In adults with psoriasis, adding methotrexate to adalimumab did not improve effectiveness or drug survival compared with adalimumab alone, according to a UK cohort study of patients with plaque psoriasis.

METHODOLOGY:

  • Researchers emulated a target trial using data on 1784 patients with moderate to severe plaque psoriasis treated with systemic medications from the British Association of Dermatologists Biologic and Immunomodulators Register between 2007 and 2021.
  • Participants received either adalimumab monotherapy (n = 1553) or adalimumab plus methotrexate (n = 231).
  • The primary outcome was the difference in adalimumab drug survival at 1 year.
  • Secondary outcomes were the proportion of patients achieving a 75% reduction in the Psoriasis Area and Severity Index (PASI 75), adverse events, and adalimumab drug and antidrug antibody levels.

TAKEAWAY:

  • Drug survival was not significantly different with combination therapy compared with adalimumab alone at 1 year (79.1% vs 78.1%) and 3 years (59.3% vs 57.2%).
  • At 1 year, PASI 75 was achieved by 52% vs 49.4% of patients in the monotherapy group vs the combination therapy group. Rates were 32.4% vs 37.2%, respectively, at 3 years.
  • Serious adverse event rates were similar between the two treatment groups: At 1 year, 7.8% vs 5.9% in the combination group vs the monotherapy group.
  • The combination therapy group had a lower antidrug antibody level (mean difference, −123.7 AU/mL) and numerically higher estimated drug concentration level (1.3 mcg/mL) than the monotherapy group.

IN PRACTICE:

“This target trial emulation cohort study did not find evidence that adding methotrexate to adalimumab was beneficial for treating plaque psoriasis,” the study authors wrote. “Future studies evaluating the effect of concomitant methotrexate should either focus on high (> 10 mg/wk) dosing regimens with biologics other than adalimumab for treating plaque psoriasis or with adalimumab for other inflammatory skin diseases,” they added.

SOURCE:

The study was led by Zenas Yiu, PhD, Centre for Dermatology Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, University of Manchester, Manchester, England, and was published online on June 4 in JAMA Dermatology.

LIMITATIONS:

Most of the study participants deviated from treatment allocation and had missing outcome data, leading to inaccuracy of relative treatment effects measured by PASI and pharmacokinetic outcomes. Effect estimates in the intervention group lacked precision across all outcomes. Quality-of-life outcomes and baseline adjustment were omitted due to high levels of missing data. As an observational study, participants were unblinded to treatment allocation, introducing potential detection bias.

DISCLOSURES:

This study was supported by the National Institute for Health and Care Research Manchester Biomedical Research Centre. Several authors reported receiving grants or personal fees and having other ties with various sources.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.



Source link : https://www.medscape.com/viewarticle/methotrexate-adds-no-benefit-adalimumab-psoriasis-study-2025a1000f16?src=rss

Author :

Publish date : 2025-06-04 15:00:00

Copyright for syndicated content belongs to the linked Source.

Previous Post

CDC Expert Resigns From COVID Vax Role; FDA to Probe Abortion Drug; Measles Update

Next Post

Rivers are leaking ancient carbon back into the atmosphere

Related Posts

Health News

MHRA Approves New Immunotherapy for Bladder Cancer

July 7, 2025
Health News

US government tests new vapour-sniffing drug detector at the border

July 7, 2025
Health News

Jessie J reveals cancer operation success

July 7, 2025
Health News

Surgery Resolves Limb Movements in Pediatric Sleep Apnea

July 7, 2025
Health News

Paclitaxel Matches Cisplatin HIPEC in Ovarian Cancer

July 7, 2025
Health News

Copeptin as a Prognostic Marker in Emergency Hyponatremia

July 7, 2025
Load More

MHRA Approves New Immunotherapy for Bladder Cancer

July 7, 2025

US government tests new vapour-sniffing drug detector at the border

July 7, 2025

Jessie J reveals cancer operation success

July 7, 2025

Surgery Resolves Limb Movements in Pediatric Sleep Apnea

July 7, 2025

Paclitaxel Matches Cisplatin HIPEC in Ovarian Cancer

July 7, 2025

Copeptin as a Prognostic Marker in Emergency Hyponatremia

July 7, 2025

T2D Tied to Mortality in Both Ischemic and Nonischemic HF

July 7, 2025

Geographic Gaps in Maternity Care Cost Lives

July 7, 2025
Load More

Categories

Archives

July 2025
MTWTFSS
 123456
78910111213
14151617181920
21222324252627
28293031 
« Jun    

© 2022 NewsHealth.

No Result
View All Result
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health

© 2022 NewsHealth.

Go to mobile version